"This is an important milestone in the development of Bracco's innovative cardiac imaging technology and the new MDS facility provides Bracco with a world-class manufacturing capability with significant capacity for future expansion to meet anticipated market growth," said Carlo Medici, President and Chief Executive Officer of Bracco Diagnostics, Inc. "MDS Nordion's unique expertise in the development and manufacture of radiopharmaceuticals, along with its highly specialized facilities, made them an obvious choice when Bracco looked to expand its CardioGen-82 production capacity."
MDS Nordion offers tailored solutions, leading expertise and service capabilities for radiopharmaceutical development, clinical and commercial manufacturing, and radiation-based medical device development. MDS Nordion has GMP-compliant facilities in Ottawa and Vancouver, Canada, and Fleurus, Belgium that can accommodate a variety of development, manufacturing, and supply requirements.
About Bracco Imaging S.p.A.
Bracco Imaging S.p.A. is one of the world's leading companies in the diagnostic imaging business. Bracco Imaging develops, manufactures, and markets diagnostic imaging agents and solutions that meet medical needs and facilitate clinical solutions. Headquartered in Milan, Italy, Bracco Imaging operates in over 80 markets worldwide, either directly or indirectly, through subsidiaries, joint ventures, licenses, and distribution partnership agreements.
Bracco Imaging is a subsidiary of Bracco S.p.A., the holding company of the Bracco Group which also markets ethical and over-the-counter (OTC) pharmaceutical products in Italy as well as advanced medical technology systems worldwide. Furthermore, the Bracco Group offers diagnosis services through the Milan-based Centro Diagnostico Italiano (Italian Diagnostic Center). For more information, vis
|SOURCE MDS Nordion|
Copyright©2009 PR Newswire.
All rights reserved